Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers

(Dana-Farber Cancer Institute) The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.